N/A
Completed N=10
Effect of MCT Emulsification on Ketogenesis in Human Adults
Healthy
Source: ClinicalTrials.gov NCT02409927 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Plasma Ketone Concentration — 136.97; 177.43; 270.61; 249.3 µmol/L
Summary
Lower brain glucose uptake is present before the onset of cognitive deterioration and may increase the risk of cognitive decline in Alzheimer's disease. Ketones are the brain's main alternative energy substrates. Medium-chain triglycerides (MCT) are rapidly beta-oxidized and are ketogenic. Large doses of MCT oil are linked to gastro-intestinal side effects due to incomplete absorption so the investigators examined whether homogenisation into a skim milk matrix (MCT-H) would both improve ketogenesis and reduce side-effects compared to MCT taken without homogenisation into a matrix (bulk MCT [MCT-B]).
Hypotheses: (i) MCT-H will be better absorbed compared to MCT-B, so MCT-H will result in higher ketonemia and lower side effects in healthy adults. (ii) The effects of MCT-B and MCT-H on ketogenesis will be dose-dependent.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma Ketone Concentration |
136.97; 177.43; 270.61; 249.3; 262.92; 277.25 | — |
| SECONDARY Plasma Glucose Concentration |
4.86; 4.98; 4.97; 4.99; 5.01; 4.84 | — |
| SECONDARY Plasma Free Fatty Acids Concentration |
0.43; 0.39; 0.41; 0.38; 0.44; 0.41 | — |
| SECONDARY Plasma Insuline Concentration |
9.79; 13.7; 10.88; 13.00; 12.87; 11.94 | — |
| SECONDARY Number of Participants With Side Effects for Each Visit |
0; 1; 4; 5; 2; 4 | — |
Eligibility Criteria
Inclusion Criteria
- aged 18 years or more
Exclusion Criteria
- smoker
- pregnancy or breastfeeding
- diabetes or insulin resistance
- uncontrolled thyroid disease, hepatic or renal disease
- uncontrolled high blood pressure
- medical treatment influencing lipid or glucide metabolism
- ongoing or past severe drug or alcohol abuse
- dementia or psychiatric difficulties or depression
- chronic immune condition or inflammation
Data sourced from ClinicalTrials.gov (NCT02409927). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.